BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1873 related articles for article (PubMed ID: 19228602)

  • 1. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
    Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
    Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors for recurrent venous thromboembolism].
    Rosencher J; Mirault T; Martinez I; Zhu T; Messas E; Emmerich J
    Rev Mal Respir; 2011 Apr; 28(4):453-62. PubMed ID: 21549901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current criteria to determine the duration of anticoagulant therapy].
    Palareti G
    Recenti Prog Med; 2007 Dec; 98(12):603-6. PubMed ID: 18369033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
    Novacek G; Weltermann A; Sobala A; Tilg H; Petritsch W; Reinisch W; Mayer A; Haas T; Kaser A; Feichtenschlager T; Fuchssteiner H; Knoflach P; Vogelsang H; Miehsler W; Platzer R; Tillinger W; Jaritz B; Schmid A; Blaha B; Dejaco C; Eichinger S
    Gastroenterology; 2010 Sep; 139(3):779-87, 787.e1. PubMed ID: 20546736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
    Cosmi B; Legnani C; Cini M; Guazzaloca G; Palareti G
    Thromb Haemost; 2005 Nov; 94(5):969-74. PubMed ID: 16363238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation.
    Siragusa S; Anastasio R; Giarratano A; Malato A; Bonifacio G; Arcara C; Gebbia N
    Exp Oncol; 2004 Sep; 26(3):192-5. PubMed ID: 15494686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism in pregnancy.
    James AH
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):326-31. PubMed ID: 19228606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the optimal duration of treatment for DVT? An update on evidence-based medicine of treatment for DVT.
    East AT; Wakefield TW
    Semin Vasc Surg; 2010 Sep; 23(3):182-91. PubMed ID: 20826296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
    Legnani C; Mattarozzi S; Cini M; Cosmi B; Favaretto E; Palareti G
    Br J Haematol; 2006 Jul; 134(2):227-32. PubMed ID: 16846482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended treatment for venous thromboembolism: how long is long enough?
    Cosmi B; Palareti G
    Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-dimer, oral anticoagulation, and venous thromboembolism recurrence.
    Cosmi B; Palareti G
    Semin Vasc Med; 2005 Nov; 5(4):365-70. PubMed ID: 16302157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and venous thromboembolism.
    Pabinger I; Ay C
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):332-6. PubMed ID: 19228607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.